Evidence Hub

Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy

ClinicalTrials.gov · COMPLETED, 2025

100 participants

Abstract

* Detection of primary antimicrobial susceptibility and resistance of Helicobacter Pylori infection.

* Detection of resistance and virulence genes of Helicobacter Pylori infection.

* Assessment of H pylori carcinogenicity gene.

* Evaluation of outcome and efficacy of antibiotics regimen will be used in our research.

* Evaluation of effect of other factors as diet (fatty and spicy meal), drugs as NSAIDs use, antibiotics for any cause on response of H pylori to antibiotics regimen.

Conditions: H Pylori Infection.

Primary outcome: detection of pre treatment antibiotic culture and sensitivity test; detection of vacuolating cytotoxin A and cytotoxin-associated gene A virulent Helicobacter Pylori genotypes by polymerase chain reaction amplification(PCR); Relation of histopathological examination (gastritis classification) to clinical presentation and to resistance..

Enrollment: 100 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 100 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free